{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:48:58Z","timestamp":1753890538374,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["19410741000"],"award-info":[{"award-number":["19410741000"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017536","name":"Shanghai Pulmonary Hospital","doi-asserted-by":"publisher","award":["fkgg19804"],"award-info":[{"award-number":["fkgg19804"]}],"id":[{"id":"10.13039\/501100017536","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900050","82000059"],"award-info":[{"award-number":["81900050","82000059"]}],"id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014175","name":"Shanghai Municipal Health and Family Planning Commission","doi-asserted-by":"publisher","award":["20204Y0382"],"award-info":[{"award-number":["20204Y0382"]}],"id":[{"id":"10.13039\/501100014175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The 2015 European pulmonary hypertension (PH) guidelines recommend a risk stratification strategy for pulmonary arterial hypertension (PAH). We aimed to investigate the validation and potential prognostic information in Chinese patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The risk assessment variables proposed by the PH guidelines were performed by using the WHO function class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right arterial pressure, cardiac index, mixed venous saturation, right atrium area, pericardial effusion, peak oxygen consumption, and ventilatory equivalents for carbon dioxide. An abbreviated version also was applied.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 392 patients with idiopathic PAH (IPAH) were enrolled between 2009 and 2018. After a median interval of 13 months, re-evaluation assessments were available for 386 subjects. The PAH guidelines risk tool may effectively discriminate three risk groups and mortality (<jats:italic>p<\/jats:italic> &amp;lt; 0.001) both at the baseline and re-evaluation. Meanwhile, its simplified risk version was valid for baseline and accurately predicted the risk of death in all the risk groups (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). At the time of re-evaluation, the percentage of low-risk group has an increase, but a greater proportion achieved the high-risk group and a lesser proportion maintained in the intermediate-risk group.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The 2015 European PH guidelines and its simplified version risk stratification assessment present an effective discrimination of different risk groups and accurate mortality estimates in Chinese patients with IPAH. Changes of risk proportion at re-evaluation implicated that natural treatment decisions may not be consistently with goal-oriented treatment strategy.<\/jats:p>","DOI":"10.3389\/fcvm.2021.745578","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T04:57:51Z","timestamp":1637557071000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China"],"prefix":"10.3389","volume":"8","author":[{"given":"Su-Gang","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin-Hua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ci-Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Ling","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1378\/chest.11-0676","article-title":"The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension","volume":"141","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"B3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.healun.2014.09.016","article-title":"Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis","volume":"34","author":"Benza","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","article-title":"A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension","volume":"3947","author":"Kylhammar","year":"2018","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1700740","DOI":"10.1183\/13993003.00740-2017","article-title":"Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur Respir J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1700889","DOI":"10.1183\/13993003.00889-2017","article-title":"Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension","volume":"502","author":"Boucly","year":"2017","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1801889","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"Galie","year":"2019","journal-title":"Eur Respir J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.104.529800","article-title":"Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication","volume":"112","author":"Diller","year":"2005","journal-title":"Circulation."},{"key":"B9","doi-asserted-by":"publisher","first-page":"32041","DOI":"10.1016\/j.healun.2017.09.026","article-title":"Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension","volume":"2498","author":"Badagliacca","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"B10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1378\/chest.10-2327","article-title":"Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era","volume":"140","author":"Zhang","year":"2011","journal-title":"Chest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","article-title":"Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis","volume":"4","author":"Lajoie","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of Ambrisentan plus Tadalafil in pulmonary arterial hypertension","volume":"373","author":"Galie","year":"2015","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1164\/rccm.201507-1398OC","article-title":"Ambrisentan and Tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension","volume":"192","author":"Hassoun","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/eurheartj\/ehq152","article-title":"Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses","volume":"31","author":"Galie","year":"2010","journal-title":"Eur Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1164\/rccm.201207-1290OC","article-title":"Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension","volume":"187","author":"Wu","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/echo.12909","article-title":"Prognostic value of pericardial effusion on serial echocardiograms in pulmonary arterial hypertension","volume":"32","author":"Batal","year":"2015","journal-title":"Echocardiography"},{"key":"B21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ahj.2017.04.013","article-title":"High-risk echocardiographic features predict mortality in pulmonary arterial hypertension","volume":"189","author":"Austin","year":"2017","journal-title":"Am Heart J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1378\/chest.12-3033","article-title":"Pericardial effusions in pulmonary arterial hypertension: characteristics, prognosis, and role of drainage","volume":"144","author":"Fenstad","year":"2013","journal-title":"Chest"},{"key":"B23","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/echo.13531","article-title":"Maximal systolic excursion of the tricuspid annulus is independent of right atrial size and function in chronic pulmonary hypertension","volume":"34","author":"Hernandez-Suarez","year":"2017","journal-title":"Echocardiography"},{"key":"B24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijcard.2017.08.047","article-title":"Right atrial function and prognosis in idiopathic pulmonary arterial hypertension","volume":"248","author":"D'Alto","year":"2017","journal-title":"Int J Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e003521","DOI":"10.1161\/CIRCIMAGING.115.003521","article-title":"Right atrial function in pulmonary arterial hypertension","volume":"8","author":"Roca","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"B26","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/ehjci\/jes003","article-title":"The association of clinical outcome with right atrial and ventricular remodelling in patients with pulmonary arterial hypertension: study with real-time three-dimensional echocardiography","volume":"13","author":"Grapsa","year":"2012","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1513\/AnnalsATS.201610-788FR","article-title":"Cardiopulmonary exercise testing in pulmonary hypertension","volume":"14","author":"Weatherald","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"B28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1161\/hc2901.093198","article-title":"Exercise pathophysiology in patients with primary pulmonary hypertension","volume":"104","author":"Sun","year":"2001","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1161\/01.CIR.0000022687.18568.2A","article-title":"Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing","volume":"106","author":"Wensel","year":"2002","journal-title":"Circulation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.ijcard.2012.03.135","article-title":"Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension","volume":"167","author":"Wensel","year":"2013","journal-title":"Int J Cardiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/eurjhf\/hft044","article-title":"Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension","volume":"15","author":"Blumberg","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"B32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.healun.2009.09.003","article-title":"Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review","volume":"9","author":"Arena","year":"2010","journal-title":"J Heart Lung Transplant"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.745578\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T04:57:55Z","timestamp":1637557075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.745578\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":32,"alternative-id":["10.3389\/fcvm.2021.745578"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.745578","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"article-number":"745578"}}